Ruth Ann Marrie1,2,3, Lesley A Graff3,4, John D Fisk5, Scott B Patten6, Charles N Bernstein1,3. 1. Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, CANADA. 2. Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, CANADA. 3. University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, CANADA. 4. Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, CANADA. 5. Departments of Psychiatry, Psychology & Neuroscience, and Medicine, Dalhousie University, Halifax, Nova Scotia, CANADA. 6. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA.
Abstract
BRACKGROUND: We aimed to examine associations between elevated symptoms of depression and anxiety and disease activity in inflammatory bowel disease (IBD). Previous findings have been inconsistent and have not accounted for variability in the courses of these conditions over time. METHODS: We followed 247 participants with IBD (153 Crohn's disease [CD], 94 ulcerative colitis [UC]) for 3 years. Annually, participants underwent an abdominal examination, reported therapies used for IBD, and completed the Hospital Anxiety and Depression Scale (HADS) questionnaire. We evaluated associations of elevated symptoms (scores ≥11) of anxiety (HADS-A) and depression (HADS-D) with the presence of active IBD as measured using the Powell Tuck Index for UC and the Harvey-Bradshaw Disease Activity Index for CD. We employed logistic regression with generalized estimating equations, simultaneously estimating between-person and within-person effects. RESULTS: Of 247 participants, 15 (6.1%) had elevated symptoms of depression (HADS-D ≥11) at enrollment, 41 (16.6%) had elevated symptoms of anxiety (HADS-A ≥11), and 101 (40.9%) had active IBD. On average, individuals with elevated symptoms of depression (odds ratio [OR], 6.27; 95% CI, 1.39-28.2) and anxiety (OR, 2.17; 95% CI, 1.01-4.66) had increased odds of active IBD. Within individuals, elevations in symptoms of depression over time were associated with increased odds of active IBD (OR, 2.70; 95% CI, 1.15-6.34), but elevated symptoms of anxiety were not. After adjustment for covariates (including disease activity), elevated symptoms of depression were also associated with increased odds of biologic therapy use (OR, 2.02; 95% CI, 1.02-4.00). CONCLUSION: Symptoms of depression and anxiety are associated with disease activity in IBD over time. Reducing these symptoms should be incorporated into the management of IBD.
BRACKGROUND: We aimed to examine associations between elevated symptoms of depression and anxiety and disease activity in inflammatory bowel disease (IBD). Previous findings have been inconsistent and have not accounted for variability in the courses of these conditions over time. METHODS: We followed 247 participants with IBD (153 Crohn's disease [CD], 94 ulcerative colitis [UC]) for 3 years. Annually, participants underwent an abdominal examination, reported therapies used for IBD, and completed the Hospital Anxiety and Depression Scale (HADS) questionnaire. We evaluated associations of elevated symptoms (scores ≥11) of anxiety (HADS-A) and depression (HADS-D) with the presence of active IBD as measured using the Powell Tuck Index for UC and the Harvey-Bradshaw Disease Activity Index for CD. We employed logistic regression with generalized estimating equations, simultaneously estimating between-person and within-person effects. RESULTS: Of 247 participants, 15 (6.1%) had elevated symptoms of depression (HADS-D ≥11) at enrollment, 41 (16.6%) had elevated symptoms of anxiety (HADS-A ≥11), and 101 (40.9%) had active IBD. On average, individuals with elevated symptoms of depression (odds ratio [OR], 6.27; 95% CI, 1.39-28.2) and anxiety (OR, 2.17; 95% CI, 1.01-4.66) had increased odds of active IBD. Within individuals, elevations in symptoms of depression over time were associated with increased odds of active IBD (OR, 2.70; 95% CI, 1.15-6.34), but elevated symptoms of anxiety were not. After adjustment for covariates (including disease activity), elevated symptoms of depression were also associated with increased odds of biologic therapy use (OR, 2.02; 95% CI, 1.02-4.00). CONCLUSION: Symptoms of depression and anxiety are associated with disease activity in IBD over time. Reducing these symptoms should be incorporated into the management of IBD.
Authors: Taryn Lores; Charlotte Goess; Antonina Mikocka-Walus; Kathryn L Collins; Anne L J Burke; Anna Chur-Hansen; Paul Delfabbro; Jane M Andrews Journal: Clin Gastroenterol Hepatol Date: 2020-01-31 Impact factor: 11.382
Authors: Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2016-09-17 Impact factor: 11.382
Authors: Charles N Bernstein; Sunny Singh; Lesley A Graff; John R Walker; Norine Miller; Mary Cheang Journal: Am J Gastroenterol Date: 2010-04-06 Impact factor: 10.864
Authors: Kathryn A Sexton; John R Walker; Lesley A Graff; Matthew T Bernstein; Brooke Beatie; Norine Miller; Michael Sargent; Laura E Targownik Journal: Inflamm Bowel Dis Date: 2017-03 Impact factor: 5.325
Authors: Ruth Ann Marrie; Randy Walld; James M Bolton; Jitender Sareen; John R Walker; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; John D Fisk; Charles N Bernstein Journal: J Psychosom Res Date: 2017-08-01 Impact factor: 3.006
Authors: Brooke Levis; Andrea Benedetti; John P A Ioannidis; Ying Sun; Zelalem Negeri; Chen He; Yin Wu; Ankur Krishnan; Parash Mani Bhandari; Dipika Neupane; Mahrukh Imran; Danielle B Rice; Kira E Riehm; Nazanin Saadat; Marleine Azar; Jill Boruff; Pim Cuijpers; Simon Gilbody; Lorie A Kloda; Dean McMillan; Scott B Patten; Ian Shrier; Roy C Ziegelstein; Sultan H Alamri; Dagmar Amtmann; Liat Ayalon; Hamid R Baradaran; Anna Beraldi; Charles N Bernstein; Arvin Bhana; Charles H Bombardier; Gregory Carter; Marcos H Chagas; Dixon Chibanda; Kerrie Clover; Yeates Conwell; Crisanto Diez-Quevedo; Jesse R Fann; Felix H Fischer; Leila Gholizadeh; Lorna J Gibson; Eric P Green; Catherine G Greeno; Brian J Hall; Emily E Haroz; Khalida Ismail; Nathalie Jetté; Mohammad E Khamseh; Yunxin Kwan; Maria Asunción Lara; Shen-Ing Liu; Sonia R Loureiro; Bernd Löwe; Ruth Ann Marrie; Laura Marsh; Anthony McGuire; Kumiko Muramatsu; Laura Navarrete; Flávia L Osório; Inge Petersen; Angelo Picardi; Stephanie L Pugh; Terence J Quinn; Alasdair G Rooney; Eileen H Shinn; Abbey Sidebottom; Lena Spangenberg; Pei Lin Lynnette Tan; Martin Taylor-Rowan; Alyna Turner; Henk C van Weert; Paul A Vöhringer; Lynne I Wagner; Jennifer White; Kirsty Winkley; Brett D Thombs Journal: J Clin Epidemiol Date: 2020-02-24 Impact factor: 7.407
Authors: Bhautesh Dinesh Jani; David Purves; Sarah Barry; Jonathan Cavanagh; Gary McLean; Frances S Mair Journal: PLoS One Date: 2013-09-13 Impact factor: 3.240
Authors: Awni Abu Sneineh; Sara Haj Ali; Ahmad Al-Masri; Amr Diab; Farah Aldweik; Mohammad Darweesh; Mohammad Qaisi; Osama Alshakhatreh; Tarek Tamimi; Yaser Rayyan; Radwan Banimustafa; Ibrahim Sablaban Journal: Sci Rep Date: 2022-05-10 Impact factor: 4.996
Authors: Jelena Popov; Yasamin Farbod; Usha Chauhan; Mona Kalantar; Lee Hill; David Armstrong; Smita Halder; John K Marshall; Paul Moayyedi; Sharon Kaasalainen Journal: Clin Exp Gastroenterol Date: 2021-04-28
Authors: Purificación Bernabeu; Carlos van-der Hofstadt; Jesús Rodríguez-Marín; Ana Gutierrez; Miguel Raúl Alonso; Pedro Zapater; Rodrigo Jover; Laura Sempere Journal: Int J Environ Res Public Health Date: 2021-05-19 Impact factor: 3.390